Generex Launches NuGenerex Medical Marketing
MIRAMAR, Fla.--(BUSINESS WIRE)--Sep 26, 2018--Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) is pleased to announce the launch of NuGenerex Medical Marketing (NMM) ( https://nugenerexmedicalmarketingllc.com/ ) to provide in-depth patient health management services, including patient identification, acquisition and onboarding, as well as ongoing patient support services for chronic care management through a dedicated call-center. Generex is establishing NMM as an integrated sales and marketing backbone to support the previously announced plan to establish the Company as a presence in the U.S. direct-to-consumer pharmaceuticals business through a multi-channel acquisition strategy.
The NMM operations and call center are integrated with our partners’ proprietary data systems & architecture, search engine, and Customer Relationship Management (CRM) dashboard that provides the call-center team of health care professionals with tools and information needed for personalized patient support. Our team is trained in HIPAA, FTC and FDA rules to ensure fully-compliant and transparent systems and procedures. The NMM call center systems have been carefully designed to minimize staffing needs through simplified and automated processes that allow for a positive caller experience that is efficient for the company representative. Callers can be educated about their insurance coverage, availability of disease management products, and locations of a local pharmacy that can service their healthcare needs.
For the last several months, Generex has progressed in its acquisition strategy, targeting assets and organizations that provide physician management services, direct-to-patient delivery of pharmaceuticals and medical devices, back-end operations and fulfillment, medication therapy management, pharmacy adjudication, and physician order verification using proprietary Data Analytics and CRM systems.
Using an array of market-proven and fully compliant direct-to-patient outreach services, together with proprietary, integrated data systems, NMM will provide the Generex organization with national marketing and customer service capabilities. These fully HIPAA compliant systems provide targeted patient analytics to deliver a comprehensive treatment platform for coordinating support services, especially pertinent for patients with complex, chronic, and co-occurring diseases including diabetes, cardiovascular disease, rheumatoid arthritis, and chronic pain. Through an extensive pharmacy backbone and nationwide footprint, NMM plans to be a leader in the delivery, execution and adjudication of drugs, devices, laboratory services, and education to make healthcare easy for the patient.
NMM will be led by an accomplished team in the field of internet medical marketing, with deep experience in pharmaceutical and medical device sales, systems development, and data analytics. The NMM team founded one of the first on-line pharmacies in the United States, achieving annual revenues of $80 million. Subsequently, they built an on-line, direct-to-patient service for medical equipment, and started a medical technology company that assisted physicians in patient engagement services to significantly drive practice revenue.
“We are delighted to launch NuGenerex Medical Marketing as another step in our overall corporate strategy to provide end-to-end solutions that optimize patient health outcomes through a nationwide footprint for delivery of drugs, medical devices, and healthcare services,” said Joe Moscato, President & Chief Executive Officer of Generex. “With an experienced management team, we have been building the NuGenerex Medical Marketing infrastructure for several months, establishing SOPs, integrating and validating information technologies and systems, and preparing to launch sales and marketing programs to support our overall enterprise, including near-term acquisitions in the fields of managed services and pharmacy distribution. We have identified our first target acquisitions, and have been conducting the necessary due diligence work required to define payment terms, complete audits, consolidate work plans, and ultimately to line up the financing for the deals, which we expect will be announced in the near term. We are excited about the future of Generex and the realization of our vision for a new healthcare enterprise that will drive substantial revenue and significant long-term value for our investors.”
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005256/en/
CONTACT: Generex Biotechnology Corporation
Joseph Moscato, 646-599-6222
Todd Falls, 800-391-6755 Extension 222
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA
INDUSTRY KEYWORD: PRACTICE MANAGEMENT HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL COMMUNICATIONS MARKETING
SOURCE: Generex Biotechnology Corporation
Copyright Business Wire 2018.
PUB: 09/26/2018 09:00 AM/DISC: 09/26/2018 09:01 AM